抗心肌纤维化的临床治疗进展  

A Clinical Perspective in the Treatment of Cardiac Fibrosis

作　　者：魏文迎 张宁[1] 唐其柱[1] WEI Wenying;ZHANG Ning;TANG Qizhu(Dept. of Cardiology, Renmin Hospital of Wuhan University ,Wuhan 430060 ,Chin)

机构地区：[1]武汉大学人民医院心内科

出　　处：《武汉大学学报（医学版）》2018年第4期678-682,共5页Medical Journal of Wuhan University

基　　金：国家自然科学基金资助项目(编号:81470516)

摘　　要：心肌纤维化是多种心血管疾病的共同病理生理过程,虽然大量的动物实验结果提示抗心肌纤维化治疗已有长足进展,但相关临床试验结果不容乐观。同时研究发现即使对心衰患者进行传统抗心衰药物治疗,但心肌纤维化仍在持续进展,因此寻找新的有效抗心肌纤维化药物迫在眉睫。本文总结心肌纤维化治疗相关临床试验,探讨临床试验所取得进步及存在的不足,进而深入了解抗心肌纤维化治疗进展。Cardiac fibrosis is central to a broad constellation of cardiovascular diseases.Research on the mechanisms of cardiac fibrosis has advanced greatly in animal models and seems promising,however,results of clinical trials have proved to be disappointing.Cardiac fibrosis continues to aggravate in patients with heart failure even when treated with the conventional therapies.The urgent challenge we confronted with is to find novel and efficient agent to ameliorate cardiac fibrosis.In this review article,we summarize anti-fibrotic therapies in the progression of cardiac fibrosis in different clinical trials.

关 键 词：心肌纤维化 临床研究 治疗 

分 类 号：R541.3[医药卫生—心血管疾病]